- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03273608
Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients
Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients: Safety & Efficacy Registry in Taiwan (SUPER- Taiwan)
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
The purpose of this multicenter registry is to gather the safety, efficacy and survival data in intermediate and advanced HCC patients treated drug-eluting microsphere in Taiwan in order to provide clinical evidence on deTACE in HCC management to physicians in the region, and to support the application of in treating advanced HCC patients.
Primary Objective:
To collect 1-year overall survival of chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients in Taiwan.
Secondary Objectives:
- To evaluate the overall tumor response of chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients. The tumor response is according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.
- To evaluate the local tumor response (in the tumor(s) treated with drug-eluting microsphere) by chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients.
- To evaluate the safety profile of chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients.
Exploratory Objectives:
- To evaluate the downstaging and downsizing potential of chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients to within Milan Criteria and to within Resection margin.
- To collect time-to-progression (TTP) and progress-free-survival (PFS) data of chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients.
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
-
Taipei, Taiwan, 11217
- Werving
- Taipei Veterans General Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:Patients must meet all of the following inclusion criteria in order to be entered into the study:
- Age 20 or older.
- Patient has signed informed consent.
Patient must have a diagnosis of hepatocellular cancer confirmed by AASLD and at least one of the following method:
- Magnetic resonance imaging (MRI) with early enhancement and delayed enhancement washout of at least one solid liver lesion > 1 cm.
- Contrast enhanced computed tomography (CT) with early enhancement and delayed enhancement washout of at least one solid liver lesion > 1 cm.
- Histological confirmation is required for lesions with inconclusive features.
Patient must not be suitable for treatment by resection or percutaneous ablation at time of study entry.
- Patients not suitable for ablation due to lesion location may be enrolled.
- Patients with HCC recurrence but not suitable for resection or ablation maybe enrolled.
Patient MUST be with either BCLC stage B OR C, and meet the following criteria:
- Stage Child-Pugh A or B AND
- Performance status ECOG ≤ 1 WITH Vascular Invasion or WITHOUT Vascular invasion.
- Patient has a life expectancy of at least 6 months.
Exclusion Criteria:If patients meet any of the following criteria they may not be entered into the study:
- Current or previous treatment with chemo- or radiation therapy or sorafenib or drug-eluting chemoembolization (deTACE).
- Patients with concurrent cancer except non-melanomatous skin cancer.
- Female patients who are pregnant, breastfeeding, or premenopausal and not using an effective method of contraceptive.
- Performance status ECOG > 1.
- Child-Pugh Class C.
- Occlusive tumor thrombus to the main portal trunk.
- Active gastrointestinal bleeding.
- Evidence of uncorrectable bleeding diathesis.
- Extra-Hepatic spread of the HCC.
- Encephalopathy not adequately controlled medically.
- Presence of ascites not controlled medically.
- Any contraindication for MRI/ CT (eg. metallic implants).
- Allergy to contrast media that cannot be managed with prophylaxis.
- Any contraindication to arteriography.
- Any contraindication for doxorubicin administration.
- Any contraindication for hepatic embolization. Porto-systemic shunt, or an arteriovenous shunt that cannot be adequately closed prior to chemoembolization. Hepatofugal blood flow. Serum creatinine > 2mg/dL. Other condition deemed exclusionary by physician. Uncorrectable impaired clotting.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Case-Alleen
- Tijdsperspectieven: Prospectief
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Overall survival
Tijdsspanne: 1 year
|
To define all participants from the day of the first HepaSphere Treatment until end of study or death is reported, whichever comes first.
|
1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Tumor Response
Tijdsspanne: 1 year
|
Tumor response will be assessed using modified Response Evaluation Criteria In Solid Tumors (mRECIST) criteria to evaluate tumor necrosis under CT/ MRI and will be presented as %.
|
1 year
|
Adverse Event (AE)
Tijdsspanne: 1 year
|
Adverse event will be accessed according to CTCAE 4.0 after treatments until end of study or death.
|
1 year
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Exploratory Objectives, Time-To-Progression (TTP)
Tijdsspanne: 1 year
|
To define all participants from the day of the first HepaSphere Treatment until tumor progression or death is first reported, whichever comes first.
|
1 year
|
Exploratory Objectives, Downstaging
Tijdsspanne: 1 year
|
Tumor staging will be accessed according to BCLC staging system and Milan criteria, and will be reviewed at follow-up until end of study or death.
|
1 year
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Yi-Hsiang Huang, M.D. Ph.D., Taipei Veterans General Hospital, Taiwan
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HEPA-Taiwan-001
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hepatocellulair carcinoom
-
Hospices Civils de LyonWervingKwaadaardige tumoren als Chordoma, Adenoid Cystic Carcinoma en SarcoomFrankrijk
-
CG Oncology, Inc.BeëindigdCarcinoom in Situ | Overgangscelcarcinoom | Blaaskanker | Carcinoma in situ gelijktijdig met papillaire tumorenVerenigde Staten